Pathgenesis by the RANas with an extent of control of trinotide repecats: mechanics and therapeutic strategies (Q84328): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): Myotoic Dystrophy (DM) and Fragile X-associated tremora-taxia Syndrome (FXTAS)Boh RNAS mat sequeaster nuclear protein, and their thereof.Since the cause of molecular target is well defined, DM and FXTAS are duly amending to the development of the development of RNA.And other, with a view to producing results, in animal models of DM;they are a new tool to reduce the effect of FAS to reduce its translation rate.Iim to achieve the gene that shall...) |
(Created claim: summary (P836): Myotonic Dystrophy (DM) and Fragile X-associated tremor-Ataxia Syndrome (FXTAS) are dominant disorders caused by RNA gain of function of expanded CUG or CGG repeats. Both RNAs may sequester nuclear proteins, and their repeat sequences Undergo untypical translation into toxic mono-amino acid peptides. Since the causative molecular target is well defined, DM and FXTAS are highly amenable to the development of RNA targeting therapy. We and others d...) |
||||||||||||||
| Property / summary | |||||||||||||||
Myotonic Dystrophy (DM) and Fragile X-associated tremor-Ataxia Syndrome (FXTAS) are dominant disorders caused by RNA gain of function of expanded CUG or CGG repeats. Both RNAs may sequester nuclear proteins, and their repeat sequences Undergo untypical translation into toxic mono-amino acid peptides. Since the causative molecular target is well defined, DM and FXTAS are highly amenable to the development of RNA targeting therapy. We and others demonstrated that reduction of protein sequestration on toxic CUG repeats using various oligonucleotide-based approaches or small compounds led to promising results in animal models of DM; therefore, now we want to develop similar tools to reduce the effect of FXTAS mutation by targeting RNA with CGG expansion, to reduce its translation rate. We also aim to achieve the gene therapy tool to overexpress the therapeutic proteins which may rescue nuclear proteins from pathogenic sequestration in DM. We are going to study mechanisms of both diseases. (English) | |||||||||||||||
| Property / summary: Myotonic Dystrophy (DM) and Fragile X-associated tremor-Ataxia Syndrome (FXTAS) are dominant disorders caused by RNA gain of function of expanded CUG or CGG repeats. Both RNAs may sequester nuclear proteins, and their repeat sequences Undergo untypical translation into toxic mono-amino acid peptides. Since the causative molecular target is well defined, DM and FXTAS are highly amenable to the development of RNA targeting therapy. We and others demonstrated that reduction of protein sequestration on toxic CUG repeats using various oligonucleotide-based approaches or small compounds led to promising results in animal models of DM; therefore, now we want to develop similar tools to reduce the effect of FXTAS mutation by targeting RNA with CGG expansion, to reduce its translation rate. We also aim to achieve the gene therapy tool to overexpress the therapeutic proteins which may rescue nuclear proteins from pathogenic sequestration in DM. We are going to study mechanisms of both diseases. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Myotonic Dystrophy (DM) and Fragile X-associated tremor-Ataxia Syndrome (FXTAS) are dominant disorders caused by RNA gain of function of expanded CUG or CGG repeats. Both RNAs may sequester nuclear proteins, and their repeat sequences Undergo untypical translation into toxic mono-amino acid peptides. Since the causative molecular target is well defined, DM and FXTAS are highly amenable to the development of RNA targeting therapy. We and others demonstrated that reduction of protein sequestration on toxic CUG repeats using various oligonucleotide-based approaches or small compounds led to promising results in animal models of DM; therefore, now we want to develop similar tools to reduce the effect of FXTAS mutation by targeting RNA with CGG expansion, to reduce its translation rate. We also aim to achieve the gene therapy tool to overexpress the therapeutic proteins which may rescue nuclear proteins from pathogenic sequestration in DM. We are going to study mechanisms of both diseases. (English) / qualifier | |||||||||||||||
point in time: 14 October 2020
| |||||||||||||||
Revision as of 12:36, 14 October 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pathgenesis by the RANas with an extent of control of trinotide repecats: mechanics and therapeutic strategies |
Project in Poland financed by DG Regio |
Statements
3,499,222.0 zloty
0 references
3,499,222.0 zloty
0 references
100.0 percent
0 references
1 October 2018
0 references
30 September 2021
0 references
UNIWERSYTET IM. ADAMA MICKIEWICZA W POZNANIU
0 references
Q2513981 (Deleted Item)
0 references
Myotonic Dystrophy (DM) and Fragile X-associated tremor-Ataxia Syndrome (FXTAS) are dominant disorders caused by RNA gain of function of expanded CUG or CGG repeats. Both RNAs may sequester nuclear proteins, and their repeat sequences undergo untypical translation into toxic mono-amino acid peptides. Since the causative molecular target is well defined, DM and FXTAS are highly amenable to the development of RNA targeting therapy. We and others demonstrated that reduction of protein sequestration on toxic CUG repeats using various oligonucleotide-based approaches or small compounds led to promising results in animal models of DM; therefore, now we want to develop similar tools to reduce the effect of FXTAS mutation by targeting RNA with CGG expansion, to reduce its translation rate. We also aim to achieve the gene therapy tool to overexpress the therapeutic proteins which may rescue nuclear proteins from pathogenic sequestration in DM. We are going to study mechanisms of both diseases. (Polish)
0 references
Myotonic Dystrophy (DM) and Fragile X-associated tremor-Ataxia Syndrome (FXTAS) are dominant disorders caused by RNA gain of function of expanded CUG or CGG repeats. Both RNAs may sequester nuclear proteins, and their repeat sequences Undergo untypical translation into toxic mono-amino acid peptides. Since the causative molecular target is well defined, DM and FXTAS are highly amenable to the development of RNA targeting therapy. We and others demonstrated that reduction of protein sequestration on toxic CUG repeats using various oligonucleotide-based approaches or small compounds led to promising results in animal models of DM; therefore, now we want to develop similar tools to reduce the effect of FXTAS mutation by targeting RNA with CGG expansion, to reduce its translation rate. We also aim to achieve the gene therapy tool to overexpress the therapeutic proteins which may rescue nuclear proteins from pathogenic sequestration in DM. We are going to study mechanisms of both diseases. (English)
14 October 2020
0 references
Identifiers
POIR.04.04.00-00-5C0C/17
0 references